Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Appili Therapeutics Inc.
  6. Summary
    APLI   CA03783R1073

APPILI THERAPEUTICS INC.

(APLI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
11/24/2021 11/25/2021 11/26/2021 11/29/2021 11/30/2021 Date
0.165(c) 0.165(c) 0.16(c) 0.16(c) 0.15 Last
820 793 418 850 177 429 847 874 54 723 Volume
0.00% 0.00% -3.03% 0.00% -6.25% Change
More quotes
Estimated financial data (e)
Sales 2022 - - -
Net income 2022 -27,8 M -21,8 M -21,8 M
Net Debt 2022 - - -
P/E ratio 2022 -0,44x
Yield 2022 -
Sales 2023 9,53 M 7,46 M 7,46 M
Net income 2023 -12,0 M -9,39 M -9,39 M
Net Debt 2023 - - -
P/E ratio 2023 -2,52x
Yield 2023 -
Capitalization 11,4 M 8,91 M 8,92 M
Capi. / Sales 2022 -
Capi. / Sales 2023 1,20x
Nbr of Employees 15
Free-Float 78,8%
More Financials
Company
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is focused on the acquisition and development of medicines targeting infectious disease. The Company also focused on building and advancing a diverse portfolio of anti-infective programs. Its anti-infective portfolio includes ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir. The ATI-2307 is used for the treatment of invasive... 
More about the company
Ratings of Appili Therapeutics Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about APPILI THERAPEUTICS INC.
11/22Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Stud..
AQ
11/19Appili Details "Positive" One Year Challenge Results from Preclinical Study Evaluating ..
MT
11/19Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Stud..
BU
11/19Appili Therapeutics Inc. Announces Positive One Year Challenge Results from Preclinical..
CI
11/19Appili Therapeutics Inc. Announces Resignation of Josef Vejvoda from the Board of Direc..
CI
11/15Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan..
AQ
11/12Appili Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months..
CI
11/12Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fis..
BU
11/12Appili Therapeutics Inc. Announces Executive Changes
CI
11/12IIROC Trade Resumption - APLI
AQ
11/12Appili Therapeutics Says Phase 3 PRESECO Clinical Trial Did Not Meet Primary Endpoint
MT
11/12Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan..
BU
11/12Appili Therapeutics Inc. Provides Update on Phase 3 PRESECO Clinical Trial Evaluating A..
CI
11/11IIROC Trading Halt - APLI
AQ
10/14APPILI THERAPEUTICS : Closes Public Offering of Near $7 Million
MT
More news
News in other languages on APPILI THERAPEUTICS INC.
10/07Appili Therapeutics propose un placement d'actions sur le marché du jour au lendemain -..
09/20Appili Therapeutics augmente de 1% après avoir obtenu un million de dollars de FUJIFILM..
09/17Appili Therapeutics en hausse de 5 % après la fin du recrutement des patients de la sou..
08/18Appili Therapeutics en hausse de 2,9 % après avoir annoncé la conclusion d'un accord de..
08/13MISE À JOUR : Appili Therapeutics perd 1,4 % et creuse sa perte nette au premier trimestre..
More news
Chart APPILI THERAPEUTICS INC.
Duration : Period :
Appili Therapeutics Inc. Technical Analysis Chart | APLI | CA03783R1073 | MarketScreener
Technical analysis trends APPILI THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 0,16 CAD
Average target price 0,72 CAD
Spread / Average Target 348%
EPS Revisions
Managers and Directors
Armand L. Balboni Chief Executive Officer & Director
Kenneth G. Howling Chief Financial Officer
Ian C. Mortimer Chairman
Yoav Golan Chief Medical Officer
Theresa Matkovits Independent Director
Sector and Competitors
1st jan.Capi. (M$)
APPILI THERAPEUTICS INC.-87.70%9
GILEAD SCIENCES, INC.21.27%88 622
BIONTECH SE344.70%87 556
REGENERON PHARMACEUTICALS35.46%68 421
WUXI APPTEC CO., LTD.27.38%66 062
VERTEX PHARMACEUTICALS-19.56%48 336